Stockscreener 앱 받기
33.07
8.96%
-3.36
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis (NASDAQ:EXEL) Trading Down 5.6%Should You Sell? - MarketBeat
Exelixis falls 8% on abstract for colorectal cancer candidate zanzalintinib - Seeking Alpha
Exelixis' (EXEL) Buy Rating Reiterated at Guggenheim - MarketBeat
Revenues, Treatment Pipeline Driving Exelixis Higher - FX Empire
What Makes Exelixis (EXEL) an Investment Bet? - Insider Monkey
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Exelixis sets 2025 guidance in line with estimates - MSN
Should You Be Adding Exelixis (NASDAQ:EXEL) To Your Watchlist Today? - Yahoo Finance
EXEL (Exelixis) Long-Term Debt & Capital Lease Obligation : $194 Mil (As of Sep. 2024) - GuruFocus.com
Exelixis (NASDAQ:EXEL) Given New $41.00 Price Target at Oppenheimer - MarketBeat
FY2024 EPS Estimates for Exelixis Increased by Analyst - MarketBeat
Institutional investors control 74% of Exelixis, Inc. (NASDAQ:EXEL) and were rewarded last week after stock increased 5.9% - Simply Wall St
Tallon Kerry Patrick Invests $2.62 Million in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis price target raised to $41 from $38 at Oppenheimer - MSN
Oppenheimer bullish on Exelixis stock as cabo sales and R&D progress impress - MSN
Exelixis's SWOT analysis: cabozantinib drives growth as stock faces ip challenges - Investing.com India
Exelixis stock hits 52-week high at $36.98 amid robust growth - Investing.com Nigeria
Exelixis (NASDAQ:EXEL) Hits New 52-Week High on Analyst Upgrade - MarketBeat
15 Analysts Have This To Say About Exelixis - Benzinga
Truist Financial Issues Positive Forecast for Exelixis (NASDAQ:EXEL) Stock Price - MarketBeat
Burney Co. Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
FY2025 EPS Estimates for Exelixis Lifted by William Blair - MarketBeat
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Exelixis stock hits 52-week high at $36.98 amid robust growth By Investing.com - Investing.com South Africa
Exelixis: Truist raises price target citing increased sales potential - Investing.com
Long Term Trading Analysis for (EXEL) - Stock Traders Daily
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again - MSN
FY2024 EPS Estimates for Exelixis Lifted by William Blair - MarketBeat
Exelixis Provides Preliminary 2024 Results and Outlook for 2025 - MSN
Exelixis says no FDA AdCom for Cabometyx label expansion - MSN
Exelixis (NASDAQ:EXEL) Price Target Raised to $37.00 at Piper Sandler - MarketBeat
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 - BioSpace
Exelixis Reports Strong $1.8B Revenue for 2024, Projects Growth in 2025 with New Cancer Drug Expansion - StockTitan
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib - MSN
Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza (EXEL) - Seeking Alpha
Exelixis Inc. Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (Cabometyx®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Marketscreener.com
Exelixis Notified by FDA That Cabozantinib Application Won't Be Discussed at Meeting - Marketscreener.com
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX - Business Wire
Range Financial Group LLC Purchases New Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis (NASDAQ:EXEL) Given New $42.00 Price Target at Guggenheim - MarketBeat
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth? - MSN
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 - Business Wire
Exelixis CEO to Present Corporate Strategy at J.P. Morgan Healthcare Conference 2025 - StockTitan
Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
0.75%
8.29%
자본화:
|
볼륨(24시간):